市场调查报告书
商品编码
1408042
全球 DNA 定序市场评估,按产品类型、技术、应用、最终用户、地区、机会和预测(2017-2031 年)Global DNA Sequencing Market Assessment, By Product Type, By Technology, By Application, By End-users, By Region, Opportunities and Forecast, 2017-2031F |
全球 DNA 定序市场规模预计在 2023 年将达到 81.6 亿美元,在 2031 年将达到 245.1 亿美元,在 2024-2031 年预测期内复合年增长率为 14.74%。 囊性纤维化等慢性疾病和其他遗传性疾病可以透过DNA定序进行高精度诊断,增加了市场需求。 越来越多的基因研究人员用于药物开发、农业研究和法医学等各种目的,创造了对 DNA 定序产品的巨大需求,进一步推动了市场的发展。 技术进步和政府对科学研究和开发的支持预计将在市场发展中发挥关键作用。 然而,与产品相关的高成本、缺乏高技能专业人员以及复杂的数据解释正在限制市场的成长。
慢性病和遗传病患疾病率的增加是 DNA 定序市场的关键驱动因素。 癌症、心血管疾病和其他慢性疾病的发生率和盛行率不断上升,刺激了对基于 DNA 定序的诊断的需求并推动市场成长。 DNA定序在这些疾病的诊断和治疗中发挥重要作用,导致对相关产品和服务的需求增加。 DNA 定序技术能够识别特定疾病标记并预测个体对治疗的反应,这正在推动其采用并进一步促进市场扩张。 根据世界卫生组织 2023 年 9 月的说明书,非传染性疾病 (NCD) 每年导致 4,100 万人死亡,占全球死亡人数的 74%。 约 1700 万人在 70 岁时死于非传染性疾病,其中 86% 发生在低收入和中等收入国家。 大多数非传染性疾病死亡是由心血管疾病(CVD)引起的,其次是癌症、慢性呼吸道疾病和糖尿病。
探索基因组并将其利润用于各种目的的研究和开发的成长正在对市场产生积极影响。 在过去的几十年里,人类基因组计画为扩大研究领域(包括基因组探索)做出了重大贡献。 同时,由于学术/组织研究计画中对桑格技术和NGS的接受和利用不断增加,市场预计将出现显着增长。
由于研发活动的高投资、主要参与者的技术开发以及先进的医疗基础设施,美国和加拿大等北美国家预计将以最高的价值份额主导市场。 政府对各种 DNA 定序技术的支援活动正在推动该地区的市场成长。
COVID-19 大流行对市场产生了重大影响。 与 COVID-19 相关的护理的优先顺序增加了 DNA 定序方法的使用来对抗这种病毒,同时减少了其他方法的使用。 新一代定序方法引起了人们对 COVID-19 诊断的极大兴趣。 2021 年 COVID-19 患者的增加显着增加了对包括 DNA 定序在内的诊断产品的需求,推动了市场成长。 此外,疫情对DNA定序市场的供应链产生了负面影响,在一定程度上抑制了成长,但在疫情限制解除后,市场很快就恢復了正常节奏,并在预测期内实现了稳定成长。预计会被记录。
本报告研究和分析了全球 DNA 定序市场,提供市场规模和预测、市场动态以及主要参与者的现状和前景。
Global DNA sequencing market size was valued at USD 8.16 billion in 2023, which is expected to reach USD 24.51 billion in 2031, with a CAGR of 14.74% for the forecast period between 2024 and 2031F. The global DNA sequencing market is a highly dynamic and promising market with a robust product and favorable market strategies. Healthcare professionals can diagnose chronic diseases with pinpoint accuracy which can facilitate the drafting of effective treatment and disease management strategies. Genetic mutation leading to chronic disease can be detected early using DNA sequencing. Several chronic diseases and other genetic disorders like cystic fibrosis are diagnosed using DNA sequencing with high precision, thus there is a growing demand for the market. The increasing number of genetic researchers for different purposes, like drug development, agricultural research, and forensics, creates a huge demand for DNA sequencing products, further driving the market. Technological advancements and government support for scientific research and development are expected to play a pivotal role in developing the market. However, the high cost associated with products, the lack of highly skilled professionals, and the interpretation of complicated data are some of the hindrances in the growth of the global DNA sequencing market.
In September 2023, Integrated DNA Technologies (IDT), announced the launch of xGen NGS products designed exclusively for the Ultima Genomics UG 100™ platform. The launch package of new xGen NGS tools comprised of adapters, primers, and universal blockers. It can support a wide range of applications, including DNA, RNA, and methylation sequencing workflows. The xGen NGS aims to minimize the possible errors in sequencing, thus improving overall outcomes.
The growing prevalence of chronic diseases and genetic disorders is a significant driver of the DNA sequencing market. The increasing incidence and prevalence of cancer, cardiovascular diseases, and other chronic ailments are fueling the demand for DNA sequencing-based diagnosis, driving market growth. DNA Sequencing plays a substantial role in the diagnosis and treatment of these diseases, leading to a rising demand for related products and services. The ability of DNA sequencing techniques to identify specific disease markers and predict individual responses to treatments is driving their adoption, further contributing to market expansion. In September 2023, according to a factsheet by WHO, noncommunicable diseases (NCDs) are responsible for killing 41 million people each year, equivalent to 74% of all deaths globally. Around 17 million people die from an NCD before the age of 70 years; 86% of these premature deaths occur in low- and middle-income countries. Cardiovascular diseases (CVDs) account for most NCD deaths, (17.9 million people annually), followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million).
Growing research and development around genome exploration and utilizing its benefits for several purposes is positively impacting the global DNA sequencing market. The human genome project contributed a lot in the past few decades to the increasing research environment involving genome expeditions. Along with that, increased acceptance, and usage of sanger technology and NGS in academic and institutional research projects, the market is expected to register significant growth. In November 2023, UK Biobank Limited released the world's largest-by-far single set of sequencing data in the public domain after consistent research for five years with an investment of EUR 200 million. The data is set to drive the discovery of novel diagnostics, treatments, and cures. The data is available to approved researchers worldwide, via a protected database containing only de-identified data.
Sanger sequencing is considered as a standard for accurate detection of single nucleotide variants and small insertions/deletions, thus it is usually preferred over other sequencing methods. With the increasing use of sanger sequencing, this segment is expected to dominate the technology category in the DNA sequencing market throughout the forecast period. Various market players are dedicated to providing better DNA sequencing services and expanding their market. In June 2023, Source Genomics, a subsidiary of Source BioScience group, announced the opening of its new laboratory in the North of England which aims to provide improved Sanger sequencing services to the northern region of England with faster turnaround time.
With high investment in research and development activities, technological advancements by key players, and highly advanced healthcare infrastructure in North American countries, like the United States and Canada, are expected to dominate the market with the highest value share. The supportive government initiatives for different DNA sequencing techniques are embracing the growth of market in the region. In May 2023, The National Institutes of Health (NIH) launched a new program, the Common Fund's Somatic Mosaicism Across Human Tissues (SMaHT) Network worth USD 140 million to explore knowledge about genetic variation in normal human cells and tissues.
The COVID-19 pandemic had a significant impact on DNA Sequencing market. The prioritization of COVID-19-related care led to an increase in the use of DNA sequencing methods for addressing the virus but simultaneously reduced other applications. Next-generation sequencing methods gained huge interest in the diagnosis of COVID-19. Rising COVID-19 cases in the year 2021 significantly boosted the demand for diagnostic products involving DNA sequencing, propelling the market growth. Furthermore, the pandemic negatively influenced the supply chain in the DNA Sequencing market, limiting the growth to some extent, but the market resumed to its usual pace soon after the pandemic restrictions were waived off and is expected to register consistent growth during the forecast period.
To increase their presence globally, major companies in the market are undertaking strategies such as product launches, mergers and acquisitions, and partnerships. In October 2022, PacBio announced the launch of their two new sequencing platforms, Revio and Onso. Revio is a short-read sequencing system while Onse is a long-read DNA sequencing platform for improving the sequencing outcomes of researchers. The Revio System has a U.S. list price of USD 779,000 while Onso has a U.S. list price of USD 259,000.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.